Antipsychotic drugs are widely used to treat abnormal behaviour particularly that related to the functional psychoses such as schizophrenia. This review discusses the pharmacokinetics and pharmacology of antipsychotic drugs like chlorpromazine. Clinical use comprises the induction of tranquillization in disturbed psychiatric patients, the treatment of acute and chronic schizophrenic symptoms, and the postponement of relapse in such patients. Unwanted effects are multifarious, involving many systems of the body. Extrapyramidal signs and symptoms are particularly noticeable, and the chronic type, tardive dyskinesia, is a major problem.
MeltzerHY: Novel approaches to the pharmacotherapy of schizophrenia. Drug Dev Res1986; 9: 23–40.
2.
CurrySH: The strategy and value of neuroleptic drug monitoring. J Clin Psychopharmacol1985; 5: 263–271.
3.
CurrySHD'MelloAMoundGP: Destruction of chlorpromazine during absorption in the rat in vivo and in vitro. Br J Pharmacol1971; 42: 403–411.
4.
SakalisGChanTLGershonS: The possible role of metabolites in therapeutic response to chlorpromazine treatment. Psychopharmacologia1973; 32; 279–284.
5.
CurrySHMarshallJHLDavisJM: Chlorpromazine plasma level and effects. Arch Gen Psychiatry1970; 22: 289–296.
6.
MayPRAvan PuttenT: Plasma levels of chlorpromazine in schizophrenia: a critical review of the literature. Arch Gen Psychiatry1978; 35: 1081–1087.
7.
KucharskiLTAlexanderPTuneL: Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients. Psychopharmacology1984; 82: 194–198.
8.
BrownWALaughrenTChisholmE: Low serum neuroleptic levels predict relapse in schizophrenic patients. Arch Gen Psychiatry1982; 39: 998–1000.
9.
KrskaJSampathGShahA: Radioreceptor assay of serum neuroleptic levels in psychiatric patients. Br J Psychiatry1986; 148: 187–193.
10.
TangSW: Prediction of treatment response in schizophrenia: clinical use of neuroleptic blood levels. Can J Psychiatry1985; 30: 249–250.
11.
JannMWEreshefskyLSakladSR: Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet1985; 10: 315–333.
12.
CarlssonA: Does dopamine play a role in schizophrenia?Psychol Med1977; 7: 583–597.
13.
PeroutkaSJSnyderSH: Relationship of neuroleptic drug effects at brain dopamine, serotonin, β-adrenergic and histamine receptors to clinical potency. Am J Psychiatry1980; 137: 1518–1522.
14.
FardeLWieselF-AHalldinC: Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry1988; 45: 71–76.
15.
CreeseIBurtDRSnyderSH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science1976; 192: 481–483.
16.
SnyderSH: Dopamine receptor, neuroleptics and schizophrenia. Am J Psychiatry1981; 138: 460–466.
17.
PfefferJM: Management of the acutely disturbed patient on the general ward. Br J Hosp Med1981; 26: 73–78.
18.
JohnstoneECCrowTJFrithCD: The Northwick Park “functional” psychosis study: diagnosis and treatment response. Lancet1988; ii: 119–125.
19.
FreyhanFA: Therapeutic implications of differential effects of new phenothiazine compounds. Am J Psychiatry1959; 115: 577–585.
20.
KlarHSieverLJ: The psychopharmacologic treatment of personality disorders. Psychiatric Clin N Am1984; 4: 791–801.
21.
GundersonJG: Pharmacotherapy for patients with borderline personality disorder. Arch Gen Psychiatry1986; 43: 698–700.
22.
National Institute of Mental Health Psychopharmacology Service Centre: Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry1964; 10: 246–261.
23.
HanlonTEMichauxMHOtaKY: The comparative effectiveness of eight phenothiazines. Psychopharmacology1965; 7: 89–106.
24.
MayPRA: Treatment of Schizophrenia: a Comparative Study of Five Treatment Methods.New York: Science House, 1968.
25.
Quality Assurance Project: Treatment outlines for the management of schizophrenia. Aust NZ J Psychiatry1984; 18: 19–38.
26.
MayPRA: Schizoprenia–a follow-up study of results of treatment. Arch Gen Psychiatry1976; 33: 474–478.
27.
KleinDFDavisJM: Diagnosis and Drug Treatment of Psychiatric Disorders.Baltimore: Williams & Wilkins, 1969.
28.
DavisJM: Overview; maintenance therapy in schizophrenia. 1. Schizophrenia. Am J Psychiatry1975; 132: 1237–1265.
29.
PasamanickBScarpittinFRLeftonM: Home vs. hospital care for schizophrenics. J Am Med Assoc1964; 187: 177–181.
30.
HogartyGEUlrichRF: Temporal effects of drug and placebo in delaying relapse in schizophrenic out-patients. Arch Gen Psychiatry1977; 34: 297–301.
31.
LeffJPWingJK: Trial of maintenance therapy in schizophrenia. Br Med J1971; 3: 599–604.
32.
DenckerSJMalmULeppM: Schizophrenic relapse after drug withdrawal is predictable. Acta Psychiatr Scand1986; 73: 181–185.
33.
HogartyGEGoldbergSCSchoolerNR: Drug and socio-therapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Arch Gen Psychiatry1974; 31: 603–608.
34.
HogartyGEGoldbergSCSchoolerNR: Drug and socio-therapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients. Arch Gen Psychiatry1974; 31: 609–619.
35.
VaughnCELeffJP: The influence of family and social factors on the course of psychiatric illness. Br J Psychiatry1976; 129: 125–137.
36.
LeffJVaughnC: The role of maintenance therapy and relatives' expressed emotion in relapse of schizophrenia: a two-year follow-up. Br J Psychiatry1981; 139: 102–104.
37.
McMillanJFCrowTJJohnsonAL: III. Short-term outcome in trial entrants and trial eligible patients. Br J Psychiatry1986; 148: 128–133.
38.
MacMillanJFGoldACrowTJ: IV. Expressed emotion and relapse. Br J Psychiatry1986; 148: 133–143.
39.
JohnsonDAW: Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia. Br J Hosp Med1977; 17: 546–558.
40.
JohnsonDAW: The long-acting depot neuroleptics. In: Recent Advances in Clinical Psychiatry (Granville-GrossmanK, ed). Edinburgh: Churchill Livingstone, 1982; pp 243–260.
41.
JohnsonDAW: Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry1984; 45: 13–21.
42.
KaneJM: Problems of compliance in the outpatient treatment of schizophrenia. J Clin Psychiatry1983; 44: 3–6.
43.
BeresfordRWardA: Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs1987; 33: 31–49.
44.
JohnsonDAW: The expectation of outcome from maintenance therapy in chronic schizophrenic patients. Br J Psychiatry1976; 128: 246–250.
45.
StevensBC: Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community. Psychol Med1973; 3: 161–168.
46.
WattDC: Time to evaluate long-acting neuroleptics?Psychol Med1975; 5: 222–226.
47.
HeilizerF: A critical review of some published experiments with chlorpromazine in schizophrenic, neurotic and normal humans. J Chronic Dis1960; 11: 102–148.
48.
WeinbergerDRBigelowLBKleinmanJE: Cerebral ventricular enlargement in chronic schizophrenia. An association with poor responses to treatment. Arch Gen Psychiatry1980; 37: 11–13.
49.
SimpsonGMPiEHSramekJJ: Adverse effects of antipsychotic agents. Drugs1981; 21: 138–151.
50.
RupniakNMJJennerPMarsdenCD: Acute dystonia induced by neuroleptic drugs. Psychopharmacology1986; 88: 403–419.
51.
StahlSM: Akathisia and tardive dyskinesia. Arch Gen Psychiatry1985; 42: 915–917.
52.
GibbWRGLeesAJ: The clinical phenomenon of akathisia. J Neurol Neurosurg Psychiatry1986; 49: 861–866.
53.
RateyJJSalzmanC: Recognizing and managing akathisia. Hosp Community Psychiatry1984; 35: 975–977.
54.
CaroffSN: The neuroleptic malignant syndrome. J Clin Psychiatry1980; 41: 79–83.
55.
SzabadiE: Neuroleptic malignant syndrome. Br Med J1984; 288: 1399–1400.
MartinICA: Implications of phenothiazine side effects: a study of antiparkinsonian agents in an older population. Acta Psychiatr Scand1975; 51: 110–118.
62.
JohnsonDAW: Prevalence and treatment of drug-induced extrapyramidal symptoms. Br J Psychiatry1978; 132: 27–30.
JesteDVWyattRJ: Changing epidemiology of tardive dyskinesia: an overview. Am J Psychiatry1981; 138: 297–309.
65.
Task Force on Late Neurological Effects of Antipsychotic Drugs: Tardive dyskinesia: a summary of a Task Force report of the American Psychiatric Association. Am J Psychiatry1980; 137: 1163–1172.
66.
KlawansHL: Recognition and diagnosis of tardive dyskinesia. J Clin Psychiatry1985; 46: 3–7.
67.
GardosGColeJORapkinRM: Anticholinergic challenge and neuroleptic withdrawal. Arch Gen Psychiatry1984; 41: 1030–1035.
68.
GlazerWMMooreDCSchoolerNR: Tardive dyskinesia: a discontinuation study. Arch Gen Psychiatry1984; 41: 623–627.
69.
TarsyDBaldessariniRJ: The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry1977; 12: 431–450.
